Business

market mover

Vivus shares surge as FDA approves weight-loss drug

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

jewel samad/AFP/Getty Images/File 2011

Consumers can soon choose between Vivus’s new drug and Belviq, from Arena Pharmaceuticals and Eisai Co. The pills are the first approved for obesity since 1999.

Advertisement

Vivus Inc. rose the most in
almost four months after winning approval from US regulators for its obesity drug, Qsymia. Vivus plans to begin selling Qsymia in the fourth quarter, with a warning about potential heart and birth-defect risks. It may generate $1.2 billion in sales in 2016, according to the average of five analysts’ estimates.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com